SEC Form 4 · accession 0001209191-18-050064
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David P Schenkein
Officer — Chief Executive Officer · Director
Period of report
Sep 5, 2018
Accepted (ET)
Sep 7, 2018 · 4:22 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock | Sep 5, 2018 | M | 72,619 | $2.34 | A | 72,619 | D | |
| Common stock | Sep 5, 2018 | M | 2,500 | $31.64 | A | 75,119 | D | |
| Common stockF1 | holding | — | — | — | 271,772 | I | See footnote | |
| Common stockF2 | holding | — | — | — | 79,082 | I | See footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F3 | $2.34 | Sep 5, 2018 | M | 72,619 | D | — | Apr 5, 2022 | Common stock | 72,619 | 0 | D |
| Stock option (right to buy)F4 | $31.64 | Sep 5, 2018 | M | 2,500 | D | — | Mar 4, 2024 | Common stock | 2,500 | 146,201 | D |
Explanation of responses
- F1Shares held by David P. Schenkein 2004 Revocable Trust, of which the reporting person is trustee and beneficiary.
- F2Shares held by Amy P. Schenkein 2004 Revocable Trust, of which the reporting person's spouse is trustee and beneficiary.
- F3This option was granted on April 6, 2012 for the purchase of 72,727 shares of common stock. The option vests as to 25% of the shares upon the achievement of a performance milestone, as to an additional 50% upon the achievement of a second performance milestone, and as to the remaining 25% on the first anniversary of the first date that both performance milestones were achieved. The performance criteria for the first performance milestone were met on March 18, 2013, resulting in the vesting of the option as to 18,181 shares. The performance criteria for the second performance milestone were met on April 4, 2014, resulting in the vesting of the option as to 36,364 shares, and the remaining 18,182 shares vested on April 4, 2015.
- F4This option was granted on March 5, 2014. The shares underlying this option vest as to 25% of the underlying shares on March 5, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter.